MX2024006897A - Moduladores de polipeptidos. - Google Patents
Moduladores de polipeptidos.Info
- Publication number
- MX2024006897A MX2024006897A MX2024006897A MX2024006897A MX2024006897A MX 2024006897 A MX2024006897 A MX 2024006897A MX 2024006897 A MX2024006897 A MX 2024006897A MX 2024006897 A MX2024006897 A MX 2024006897A MX 2024006897 A MX2024006897 A MX 2024006897A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- activating
- polypeptide modulators
- isolated polypeptides
- programmed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163288330P | 2021-12-10 | 2021-12-10 | |
| PCT/US2022/081186 WO2023108073A2 (en) | 2021-12-10 | 2022-12-08 | Polypeptide modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006897A true MX2024006897A (es) | 2024-06-20 |
Family
ID=86731448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006897A MX2024006897A (es) | 2021-12-10 | 2022-12-08 | Moduladores de polipeptidos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250051419A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4444339A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024546654A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240118832A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118613277A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022405109A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3241913A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313360A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024006897A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023108073A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026519808A (ja) * | 2023-06-06 | 2026-06-18 | ジョージアミューン・インコーポレイテッド | 新規pd-l2変異体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002000692A2 (en) * | 2000-06-28 | 2002-01-03 | Genetics Institute, Llc. | Pd-l2 molecules: pd-1 ligands and uses therefor |
| US10260038B2 (en) * | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| CN106794235A (zh) * | 2014-07-18 | 2017-05-31 | 阿德瓦希斯公司 | 用于引起抗肿瘤应答的基于李斯特菌的免疫原性组合物 |
| WO2016023001A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| US11219694B2 (en) * | 2015-09-24 | 2022-01-11 | The University Of North Carolina At Chapel Hill | Methods and compositions for reducing metastases |
| CN118085109A (zh) * | 2016-08-11 | 2024-05-28 | 昆士兰医学研究所理事会 | 免疫调节化合物 |
| JP2020511144A (ja) * | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Pd−l2バリアント免疫調節タンパク質及びその使用 |
| WO2019060888A1 (en) * | 2017-09-25 | 2019-03-28 | New York University | HETÉRODIMÈRE-FC FUSION PROTEINS |
| US20210213063A1 (en) * | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| EP3908600A1 (en) * | 2019-01-11 | 2021-11-17 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Fusion protein with immunosuppressive activity |
-
2022
- 2022-12-08 MX MX2024006897A patent/MX2024006897A/es unknown
- 2022-12-08 WO PCT/US2022/081186 patent/WO2023108073A2/en not_active Ceased
- 2022-12-08 CA CA3241913A patent/CA3241913A1/en active Pending
- 2022-12-08 IL IL313360A patent/IL313360A/en unknown
- 2022-12-08 KR KR1020247022359A patent/KR20240118832A/ko active Pending
- 2022-12-08 JP JP2024533810A patent/JP2024546654A/ja active Pending
- 2022-12-08 US US18/718,397 patent/US20250051419A1/en active Pending
- 2022-12-08 EP EP22905373.1A patent/EP4444339A4/en active Pending
- 2022-12-08 AU AU2022405109A patent/AU2022405109A1/en active Pending
- 2022-12-08 CN CN202280090526.6A patent/CN118613277A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024546654A (ja) | 2024-12-26 |
| WO2023108073A3 (en) | 2023-10-19 |
| CN118613277A (zh) | 2024-09-06 |
| EP4444339A2 (en) | 2024-10-16 |
| KR20240118832A (ko) | 2024-08-05 |
| CA3241913A1 (en) | 2023-06-15 |
| AU2022405109A1 (en) | 2024-06-27 |
| US20250051419A1 (en) | 2025-02-13 |
| WO2023108073A2 (en) | 2023-06-15 |
| IL313360A (en) | 2024-08-01 |
| EP4444339A4 (en) | 2026-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer | |
| Mediavilla-Varela et al. | A novel antagonist of the immune checkpoint protein adenosine A2a receptor restores tumor-infiltrating lymphocyte activity in the context of the tumor microenvironment | |
| Moretta et al. | Human natural killer cells: molecular mechanisms controlling NK cell activation and tumor cell lysis | |
| SG10201914109VA (en) | Novel anti-pd-1 antibodies | |
| WO2021007428A3 (en) | Molecules, compositions and methods for treatment of cancer | |
| KR102721494B1 (ko) | 고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도 | |
| NZ750005A (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
| WO2019241802A3 (en) | Methods of inhibiting proliferative cells | |
| WO2016022994A3 (en) | High affinity pd-1 agents and methods of use | |
| MA42895A (fr) | Cellules modifiées pour thérapie cellulaire adoptive | |
| AU2003288675A8 (en) | Antibodies against PD-1 and uses therefor | |
| WO2005020921A3 (en) | C-kit modulators and methods of use | |
| ZA202107947B (en) | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer | |
| ZA202206994B (en) | Pharmaceutical composition for treatment of cancer, comprising immune checkpoint inhibitor and fusion protein including il-2 protein and cd80 protein | |
| WO2021202780A3 (en) | Methods and compositions for treating cancer | |
| WO2021231741A3 (en) | Anti-pd-l1 antibodies and anti-pd-l1/il10 fusion proteins | |
| WO2021262880A3 (en) | Anti-pd-1 antibodies and fusion proteins | |
| WO2023108073A3 (en) | Polypeptide modulators | |
| PH12022553181A1 (en) | Anti-pd-1 antibodies | |
| Dogan et al. | Impact of neutrophil-lymphocyte and platelet-lymphocyte ratio on antiEGFR and bevacizumab efficacy in metastatic colorectal cancer | |
| Wesselborg et al. | Triggering via the alternative CD2 pathway induces apoptosis in activated human T lymphocytes | |
| Kreutzman et al. | Immunomodulatory effects of tyrosine kinase inhibitors | |
| Brown et al. | Prednisolone modulates CD8⁺ and regulatory T-cell activity to dampen response to immune checkpoint inhibitor therapy in melanoma | |
| WO2024254273A3 (en) | Novel pd-l2 mutants | |
| WO2004075839A3 (en) | Methods and compositions for modulating apoptosis |